Invivyd Inc. (IVVD NASDAQ) stock market data APIs
$1.6338
0.14(8.6%)
as of October 14, 2025
Try our APIs with
free plan!
Invivyd Inc. Financial Data Overview
Price chart is built with
Anychart
Invivyd, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's pipeline includes PEMGARDA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate, which is in preclinical studies for the prevention or treatment of COVID-19; and Adintrevimab that is in phase 2/3 clinical trials for the prevention and treatment of COVID-19. It also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. The company has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.
Prev. Close
1.6338
Open
1.7688
High
1.8237
Low
1.5659
52 wk Range
0.355-2.74
Market Cap
349 M
Shares Outstanding
214 M
Revenue
46 210 K
EPS
-0.12
Beta
0.573
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Invivyd Inc. data using free add-ons & libraries
Get Invivyd Inc. Fundamental Data
Invivyd Inc. Fundamental data includes:
- Net Revenue: 46 210 K
- EBITDA: -111 849 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-15
- EPS/Forecast: -0.02
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Invivyd Inc. News
New
Invivyd Gets FDA Clearance To Start Clinical Trials For COVID-19 Antibody VYD2311
(RTTNews) - Invivyd, Inc. (IVVD) Monday announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application for VYD2311, a vaccine alternati...
Invivyd Announces U.S. IND Clearance and Alignment with U.S. FDA on Pivotal Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID
The DECLARATION (safety and efficacy vs. placebo) and LIBERTY (exploratory safety head-to-head and combination with mRNA-based COVID vaccination) clinical trials are expected to begin around year-end ...
Invivyd Appoints Paul B. Bolno, M.D. to Its Board of Directors
NEW HAVEN, Conn., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ: IVVD) today announced the appointment of Paul B. Bolno, M.D., to its Board of Directors and as a member of the Compensatio...
Invivyd, Inc. (IVVD) Secures FDA Path for COVID-19 Antibody Approval
In this article, we will be taking a look at the 15 Best Biotech Penny Stocks to Invest in Right Now. Invivyd, Inc. stands among them. Invivyd, Inc. (NASDAQ:IVVD) is a commercial-stage biopharmaceuti...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
